Enanta Pharma Q1 2025 Update: Financials and Equity Awards

TL;DR

Enanta Pharma's Q1 2025 10-Q shows money market funds, treasury securities, and employee stock awards.

AI Summary

Enanta Pharmaceuticals Inc. filed its 10-Q for the period ending December 31, 2024. The filing details financial information for the first quarter of fiscal year 2025, including assets such as money market funds and U.S. Treasury securities, and expenses related to general and administrative functions. It also mentions equity awards like restricted stock units and stock options granted to employees.

Why It Matters

This filing provides investors with a snapshot of Enanta's financial health and operational activities for the first quarter of fiscal year 2025, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.

Key Numbers

• 2024-12-31 — Period End Date (Financial reporting period)
• 2024-09-30 — Previous Period End Date (Comparison point for financial data)

Key Players & Entities

• ENANTA PHARMACEUTICALS INC (company) — Filer
• 2024-12-31 (date) — Period End Date
• 2025-02-12 (date) — Filing Date
• 4 KINGSBURY AVENUE (address) — Business Address
• WATERTOWN (city) — Business Address City
• MA (state) — Business Address State
• 02472 (zip_code) — Business Address Zip

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share ENTA NASDAQ Indicate by

Filing Documents

• enta-20241231.htm (10-Q) — 1591KB
• enta-ex10_1.htm (EX-10.1) — 162KB
• enta-ex10_2.htm (EX-10.2) — 132KB
• enta-ex31_1.htm (EX-31.1) — 12KB
• enta-ex31_2.htm (EX-31.2) — 12KB
• enta-ex32_1.htm (EX-32.1) — 12KB
• img216988758_0.jpg (GRAPHIC) — 1418KB
• 0000950170-25-018810.txt ( ) — 10375KB
• enta-20241231.xsd (EX-101.SCH) — 925KB
• enta-20241231_htm.xml (XML) — 1285KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.

Controls and Procedures

Controls and Procedures 26 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 26 Item 1A.

Risk Factors

Risk Factors 26 Item 5. Other Information 26 Item 6. Exhibits 27

Signatures

Signatures 28 NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q ("Quarterly Report") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, forward-looking statements may be identified by words such as "anticipate," "believe," "continue," "could," "design," "estimate," "expect," "intend," "may," "plan," "potentially," "predict," "project," "should," "will" or the negative of these terms or other similar expressions. We caution you that the foregoing list may not encompass all of the forward-looking statements made in this Quarterly Report. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, including risks described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2024 and as updated in Item 1A herein. 2 PAR T I—UNAUDITED FINANCIAL INFORMATION IT EM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ENANTA PHARMACEUTICALS, INC. CONDENSED CONS OLIDATED BALANCE SHEETS (unaudited) (in thousands, except per share data) December 31, September 30, 2024 2024 Assets Current assets: Cash and cash equivalents $ 84,349 $ 37,233 Short-term marketable securities 132,342 210,953 Accounts receivable 7,718 6,646 Prepa

View Full Filing

View this 10-Q filing on SEC EDGAR